198 related articles for article (PubMed ID: 32593917)
21. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
Song SG; Lee J; Koh J; Kim S; Chung DH; Jeon YK
Diagn Cytopathol; 2020 Apr; 48(4):291-299. PubMed ID: 31930724
[TBL] [Abstract][Full Text] [Related]
22. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
[TBL] [Abstract][Full Text] [Related]
23. Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma.
Hernandez A; Brandler TC; Chen F; Zhou F; Xia Y; Zhong J; Moreira AL; Simms A; Sun W; Wei XJ; Simsir A
Am J Clin Pathol; 2020 Sep; 154(4):517-524. PubMed ID: 32589185
[TBL] [Abstract][Full Text] [Related]
24. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
Dietel M; Savelov N; Salanova R; Micke P; Bigras G; Hida T; Antunez J; Guldhammer Skov B; Hutarew G; Sua LF; Akita H; Chan OSH; Piperdi B; Burke T; Khambata-Ford S; Deitz AC
Lung Cancer; 2019 Aug; 134():174-179. PubMed ID: 31319978
[TBL] [Abstract][Full Text] [Related]
25. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
[TBL] [Abstract][Full Text] [Related]
26. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
[TBL] [Abstract][Full Text] [Related]
27. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN
Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383
[TBL] [Abstract][Full Text] [Related]
28. Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses.
Basu A; Chiriboga L; Narula N; Zhou F; Moreira AL
J Histotechnol; 2020 Dec; 43(4):174-181. PubMed ID: 33245263
[TBL] [Abstract][Full Text] [Related]
29. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Skov BG
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
[TBL] [Abstract][Full Text] [Related]
30. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression in NSCLC: Role of cell blocks and concordance between samples.
Ambrosini-Spaltro A; Dubini A; Pieri F; Ravaglia C; Delmonte A; Poletti V
Diagn Cytopathol; 2021 Feb; 49(2):303-310. PubMed ID: 33091231
[TBL] [Abstract][Full Text] [Related]
32. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
[TBL] [Abstract][Full Text] [Related]
33. Malignant pleural effusion cell blocks are reliable resources for PD-L1 analysis in advanced lung adenocarcinomas: a concordance study with matched histologic samples.
Mahajan S; Nambirajan A; Gupta I; Gupta N; Gupta P; Jain D
J Am Soc Cytopathol; 2022; 11(5):253-263. PubMed ID: 35589508
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
Keppens C; Dequeker EM; Pauwels P; Ryska A; 't Hart N; von der Thüsen JH
Virchows Arch; 2021 May; 478(5):827-839. PubMed ID: 33275169
[TBL] [Abstract][Full Text] [Related]
35. Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations.
Gagné A; Wang E; Bastien N; Orain M; Desmeules P; Pagé S; Trahan S; Couture C; Joubert D; Joubert P
J Thorac Oncol; 2019 Dec; 14(12):2062-2070. PubMed ID: 31494258
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma.
Hernandez A; Brandler TC; Zhou F; Moreira AL; Schatz-Siemers N; Simsir A
Am J Clin Pathol; 2019 Mar; 151(4):403-415. PubMed ID: 30534975
[TBL] [Abstract][Full Text] [Related]
37. Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.
Koomen BM; Badrising SK; van den Heuvel MM; Willems SM
Histopathology; 2020 May; 76(6):793-802. PubMed ID: 31793055
[TBL] [Abstract][Full Text] [Related]
38. Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
Cooper WA; Russell PA; Cherian M; Duhig EE; Godbolt D; Jessup PJ; Khoo C; Leslie C; Mahar A; Moffat DF; Sivasubramaniam V; Faure C; Reznichenko A; Grattan A; Fox SB
Clin Cancer Res; 2017 Aug; 23(16):4569-4577. PubMed ID: 28420726
[No Abstract] [Full Text] [Related]
39. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G
J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
